A side-by-side comparison of two Healthcare investors: Perceptive Advisors (Power Score 82/100) and Shenzhen Capital Group (Power Score 80/100), both ranked among the most active firms tracked in this category.
| Perceptive Advisors | Shenzhen Capital Group | |
|---|---|---|
| Power Score™ | 82/100 | 80/100 |
| Assets Managed | Approximately $11B (across its strategies as of 30 June 2026, per the firm's own About page; the firm's Form ADV Item 5.F figure could not be read) | US$50B+ (approx.; the firm's figure is RMB 360.273bn of paid-in capital across all funds it and its subsidiaries manage at 31 December 2024, per its 2025 bond credit rating report - paid-in fund scale, not net asset value) |
| Founded | 1999 | 1999 |
| Headquarters | New York, NY | Shenzhen, China |
| Sectors | Biotech, Life Sciences, Medical Devices, Diagnostics, Digital Health, Healthcare IT | Semiconductors, Technology, Robotics, Industrial Manufacturing, Advanced Manufacturing, Clean Energy, Biotech, Pharmaceuticals, Infrastructure Software |
Perceptive Advisors is a life sciences investment manager registered with the SEC as an investment adviser (CRD 154703, SEC registration effective 4 October 2010). It says it runs four strategies. The Perceptive Life Sciences Fund invests globally in public and private companies developing biotechnology products, drugs, medical devices and diagnostics, with the majority of investments in publicly traded small and mid cap companies, and participates in growth rounds, crossover rounds, IPOs and public follow-ons. Credit Opportunities, launched with its first closed-end fund in 2014, lends to healthcare companies across biopharma, medical devices, diagnostics, digital health, women's health, life sciences research and healthcare IT, and states a range of $20M to $300M per investment and approximately $3.5B of capital raised for private credit. Capital Solutions provides structured capital to later-stage and commercial-stage life sciences companies. The venture strategy, run through the Perceptive Xontogeny Venture Funds, invests primarily at seed and Series A in biotechnology, medtech, healthtech, digital health and healthcare tools and services, states investments of $10M to $50M when leading or co-leading a Series A, states over $700M across its venture funds, and says its people take board seats. The firm describes its team as scientists, technologists, molecular biologists, MDs and PhDs.
View full Perceptive Advisors profile →Shenzhen Capital Group describes itself on its own site as a state-owned comprehensive investment group whose core business is venture capital, and says its business spans venture capital, real estate investment, public mutual funds and asset securitisation. Within venture capital it says it manages venture funds, funds of funds, S funds and buyout funds, and it has managed government guidance funds since setting up China's first government guidance sub-fund with the Suzhou municipal government in 2007 and taking on entrusted management of the Shenzhen municipal guidance fund from 2016. Chairman Zuo Ding stated in a 25 February 2026 article on the group's site that more than 85 per cent of the 1,800 plus companies the group has directly invested in are start-up stage or growth stage, that more than 90 per cent are hard technology companies, and that the focus areas cover semiconductors, robotics, new materials, biopharmaceuticals and industrial software. The group's investment departments are organised by both sector (information technology, high-end equipment, general equipment, new materials, new energy, biopharmaceuticals) and region (Greater Bay Area, North China, Northeast, Central China, Southeast, Jiangsu, Shanghai, West China). Its wholly owned subsidiary Red Soil Innovation Fund Management, set up in June 2014, was the first public mutual fund management company in China established by a private equity institution.
View full Shenzhen Capital Group profile →